Clinical Trial: An Investigational Drug in Patients with Osteoarthritis

This study is no longer recruiting patients.

Sponsored by: Merck
Information provided by: Merck

Purpose

This study was conducted to assess the safety and tolerability of an investigational drug and to evaluate its effectiveness in the treatment of osteoarthritis of the hip or knee in both men and women.

Condition Treatment or Intervention Phase
Osteoarthritis
 
Phase II
Phase III

MedlinePlus related topics:  Osteoarthritis

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study

Official Title: A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients with Osteoarthritis

Eligibility

Ages Eligible for Study:  40 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

  • Patients with osteoarthritis of the hip or knee who use current approved medication (nonsteroidal anti-inflammatory drugs (NSAIDs)) or tylenol to treat the symptoms of their osteoarthritis. Patients taking NSAIDs are required to discontinue using these drugs and their symptoms must become worse.

Exclusion Criteria:

  • Patients with certain medical conditions may not be allowed to participate. These conditions will be reviewed with the study physician.

Location Information


Pennsylvania
      Call for Information, Horsham,  Pennsylvania,  19044,  United States

More Information

Study ID Numbers:  2004_056
Record last reviewed:  September 2004
Last Updated:  October 13, 2004
Record first received:  September 23, 2004
ClinicalTrials.gov Identifier:  NCT00092755
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources